This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Prince August Wilhelm married his cousin Princess Alexandra Victoria of Schleswig-Holstein-Sonderburg-Glücksburg on 22 October 1908 at the Berliner Stadtschloss. The couple had planned to take up residence in Schönhausen Palace in Berlin, but changed their mind when his father, Kaiser Wilhelm, decided to leave his son the Villa Liegnitz in the Sanssouci Park. In 1912 their only child, Prince Alexander Ferdinand of Prussia, was born. Their Potsdam residence developed into a meeting place for artists and scholars. In the First World War, August Wilhelm was made district administrator (Landrat) of the district of Ruppin; his office and residence was now Schloss Rheinsberg. His personal adjutant Hans Georg von Mackensen played an important role in his life; the two had been close friends since August Wilhelm's youth. These "pronounced homophilic tendencies" contributed to the failure of his marriage to Princess Alexandra Victoria. The couple did not divorce while August Wilhelm's father, Kaiser Wilhelm II, was Emperor, owing to his opposition to the idea.
The meta-analysis also noted that the mechanisms of acupuncture "are clinically relevant, but that an important part of these total effects is not due to issues considered to be crucial by most acupuncturists, such as the correct location of points and depth of needling" and that acupuncture may be "associated with more potent placebo or context effects" than other treatments. Commenting on these findings, both Edzard Ernst and David Colquhoun said the results were of negligible clinical significance. A 2011 overview of Cochrane reviews found evidence that suggests acupuncture is effective for some but not all kinds of pain. A 2010 systematic review found that there is evidence "that acupuncture provides a short-term clinically relevant effect when compared with a waiting list control or when acupuncture is added to another intervention" in the treatment of chronic low back pain. Two review articles discussing the effectiveness of acupuncture, from 2008 and 2009, have concluded that there is not enough evidence to conclude that it is effective beyond the placebo effect. Acupuncture is generally safe when administered using Clean Needle Technique (CNT). Although serious adverse effects are rare, acupuncture is not without risk. Severe adverse effects, including very rarely death (five case reports), have been reported.
Kardashev believes that it is very likely that a supercivilization has already detected and observed humanity through cosmic-sized telescopes. He discusses this in a 1997 article on the subject, entitled Radioastron – a Radio Telescope Much Greater than the Earth. For this supercivilization, the science of "cosmic ethnography" must be highly developed. However, the fact that no contact has been made so far could be explained by ethical considerations of these civilizations. Based on this principle, Kardashev sees only two possible evolutionary scenarios for a supercivilization: natural evolution and evolution after contact with other extraterrestrial civilizations. He considers more likely the scenario based on contact between two highly developed, technologically and culturally advanced civilizations; this scenario, which he calls the "Urbanization Hypothesis", would result in the regrouping and unification of several civilizations within a few compact regions of the Universe. Kardashev lists, in the form of investigative tools, six possible scenarios (summarized in a table at the end of his 1997 article) that explain the evolution of a civilization. Each of the scenarios corresponds to a probability, one or more objects to be observed, an adapted procedure, and, finally the possible consequences for our civilization:
== Clinical Significance == Deficiency of glutaryl-CoA dehydrogenase causes glutaric acidemia type 1, an autosomal recessive metabolic disorder.In this disorder, impaired metabolism of glutaryl-CoA is associated with elevated levels of organic acids, including glutaric acid and 3-hydroxyglutaric acid .
=== Toxicology === A method for detecting arsenious oxide, simple arsenic, in corpses was devised in 1773 by the Swedish chemist, Carl Wilhelm Scheele. His work was expanded upon, in 1806, by German chemist Valentin Ross, who learned to detect the poison in the walls of a victim's stomach. Toxicology, a subfield of forensic chemistry, focuses on detecting and identifying drugs, poisons, and other toxic substances in biological samples. Forensic toxicologists work on cases involving drug overdoses, poisoning, and substance abuse. Their work is critical in determining whether harmful substances play a role in a person's death or impairment. read more
Sources: en.wikipedia.org
1-Acetyl-5-MeO-DMT, also known as "methyl amide 5-MeO-DMT" or as 1-acetyl-5-methoxy-N,N-dimethyltryptamine, is a psychedelic drug of the tryptamine and 5-methoxytryptamine families related to 5-MeO-DMT. It is the 1-acetyl derivative of 5-MeO-DMT. The drug is a prodrug of 5-MeO-DMT with modified pharmacokinetic properties compared to 5-MeO-DMT in rodents. It is assumed to be cleaved into 5-MeO-DMT by amidase enzymes. Various analogues of 1-acetyl-5-MeO-DMT that are likewise 5-MeO-DMT or dimethyltryptamine (DMT) prodrugs have also been described and have shown widely varying pharmacokinetic parameters, for instance half-life. 1-Acetyl-5-MeO-DMT was first described in the literature in a patent by Terran Biosciences in 2023. It has been one of the major prodrug compounds highlighted from the patent.
Beryllium-8 decays almost immediately into two alpha particles as its total energy is about 92 keV greater than that of the two alpha particles, and the Coulomb barrier to decay is negligible. This is unusual among light N = Z nuclides and creates a bottleneck in stellar nucleosynthesis, which requires that a third alpha be immediately captured, known as the fusion of three alpha particles, to form stable carbon-12 and thence all heavier elements.
Further research using tracer molecule injections to examine the function of UCN III reveals that UCN III is located rostral to the hypothalamus and projects to the ventromedial hypothalamus. It is well recognized that this brain region controls energy balance and hunger. In the same brain regions, UCN III and CRHR2 are expressed, and different physiological and behavioural processes result from their activation.
John Russell (1893–1917), recipient of the Victoria Cross, born in Holyhead Ceinwen Rowlands (1905–1983), a Welsh concert soprano and recording artist, born in Holyhead R. S. Thomas (1913–2000), a Welsh poet and Anglican priest poet, grew up in Holyhead Cledwyn Hughes, Baron Cledwyn of Penrhos (1916–2001) MP & politician, born in Holyhead, attended Ysgol Uwchradd Caergybi Barbara Margaret Trimble (1921–1995) a British writer of over 20 crime, thriller and romance novels, born in Holyhead David Crystal (born 1941) linguist and chair of the charity behind Holyhead's Ucheldre Centre, lives in Holyhead Glenys Kinnock (1944-2023) a politician, MEP, educated at Holyhead High School Dawn French (born 1957 in Holyhead) comedian and actress, co-star in French and Saunders Albert Owen (born 1959 in Holyhead) politician, MP for Ynys Môn from 2001 to 2019. Kevin Johnson (born 1960 in Holyhead), a managing partner at Medicxi Ventures, a venture capital firm Jason Evans (born 1968 in Holyhead), a Welsh photographer and lecturer on photography Ben Crystal (born 1977), an English actor, author, and producer brought up in Holyhead Gareth Williams (1978–2010) worked for GCHQ and SIS died in suspicious circumstances
=== Biosynthetic pathway === The metabolic pathway to produce ergothioneine starts with the methylation of histidine to produce histidine betaine (hercynine). The sulfur atom is then incorporated from cysteine. The biosynthetic genes of ergothioneine have been described in detail for Mycobacterium smegmatis, Neurospora crassa, Schizosaccharomyces pombe (with homologues in Aspergillus, a genus important in food fermentation), and Caldithrix abyssi. This pathway has recently also been discovered in plants. Different groups of organisms use different approaches to sulfur-addition. Aerobic bacteria and fungi use an O2-dependent reaction that is catalyzed by a mononuclear non-heme iron enzyme, with cysteine or γ-glutamylcysteine as the sulfur source. Green sulfur bacteria and some archaea use a rhodanese-like sulfur transferase to perform oxidative polar substitution. Caldithrix uses a metallopterin-dependent bifunctional enzyme that combines an N-terminal domain similar to a tungsten-dependent acetylene hydratase and a C-terminal cysteine desulfurase domain. Homologs of the Caldithrix system are found in anaerobic bacteria and some archaea.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.